Breast Cancer, Fatigue
Conditions
Keywords
Fatigue, Biomarkers, Breast Cancer
Brief summary
Fatigue is common in cancer patients receiving adjuvant chemotherapy. To further understand the mechanism of fatigue and search for potential biomarkers, we will conduct a prospective study with breast cancer patients receiving adjuvant chemotherapy.
Detailed description
Patients with breast cancer undergoing adjuvant systemic chemotherapy based on the use of anthracyclines will be screened before the start of chemotherapy. Patients whose scores on the brief fatigue inventory (BFI) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue. The patients whose fatigue won't worse following the first cycle of chemotherapy will be used as controls. We will collect blood samples of both groups before and 21 days after the start of chemotherapy. We will analyze the following biomarkers: IL2, IL10, TNF and TGFB-1 measured by amplification reaction; FSH, LH, estradiol, DHEA, DHEAS and cortisol hormones measured by chemiluminescent enzyme immunometric assay
Interventions
None listed
Sponsors
Faculdade de Medicina do ABC
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Non metastatic breast cancer; * Patients undergoing adjuvant chemotherapy
Exclusion criteria
* hypothyroidism; * Depression; * anemia; * heart disease or decompensated hypertension
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Potential biomarkers related to chemotherapy induced fatigue | 21 days after the start of chemotherapy | This study examines potential biomarkers of fatigue induced by chemotherapy both in the plasma and mononuclear fraction of the peripheral blood of patients with breast cancer |
Countries
Brazil
Contacts
Primary ContactFelipe M Cruz, PhD
Outcome results
None listed